Month: January 2013

The ICOFCV and UMH created the first Chair of physiotherapy research of Spain.

|

El ICOFCV and UMH created the first Chair of physiotherapy research of Spain. valencia, January 2013- the Dean of the College of physiotherapists of the Valencian Community (ICOFCV), Juan López Boluda, and the rector of the University Miguel Hernández (UMH) of Elche, Jesus Pastor Ciurana, have signed a collaboration agreement with the aim of creating the Research Chair in physiotherapy, the first of these characteristics of Spain. The Director of the Chair will be the lecturer in the Department of pathology and surgery of the UMH, Dulce María Fuentes Morell. The Chair aims to promote research and innovation in physiotherapy, physiotherapy in the socio-sanitary field development and the role of the physiotherapist as provider of health services to society through physical media. this Chair, launched by the ICOFCV and UMH, aims to bring social and professional reality physiotherapy exercise. To do this, both institutions aim to promote new areas of professional practice to reduce the current migration of physiotherapists to Europe, where this profession is better implanted and more developed society and, consequently, provides more work. In addition, the Chair aims to help self-employment for these professionals through the impetus of tools that enable them to successfully cope with greater starting up your own company. Actions that expand the generation of self-employment and the creation of businesses in physiotherapy will be fostered from the Chair. I.e., will be encouraged...

Read More

European Commission approves Tresiba r and Ryzodeg (R) for the treatment of diabetes.

|

The European Commission approved Tresiba ® and Ryzodeg ® for the treatment of diabetes. Copenhagen, January 2013.- the European Commission has approved the develo-location of Tresiba ® (insulin degludec) and Ryzodeg ® (degludec/insulin aspart insulin) for the treatment of diabetes in adults. This approval is extended to the 27 Member States of the European Union. Tresiba ®, commercial name of degludec insulin, is an analog of insulin of new generation, which is administered once a day and has a long-term profile. In studies following a methodology of treatment up to target, which were presented to the application for approval of the drug and that Tresiba ® was compared with insulin glargine, Tresiba ® demonstrated a lower risk of overall hypoglycaemia and nocturnal hypoglycemia, at the time that successfully reached the same reductions in HbA1c. In addition, with a duration of more than 42 hours action, Tresiba ® is the first basal insulin that people with diabetes offers the possibility of adjusting the time of injection according to your needs. For his part, Ryzodeg ®, trade name for degludec/insulin aspart insulin, is composed of analogue basal insulin from new generation degludec in a soluble formulation with insulin aspart. Ryzodeg ® can be administered once or twice daily with the main meals. In studies following a methodology of treatment up to target, which were presented to the application for approval of...

Read More

Ellipse obtained the American filtration Dual mode patent

|

Ellipse obtained the American filtration Dual mode patent. Spain, January 2013.- technology computers I²PL Ellipse relies on the principle of the mode of Dual filtration (MFD), i.e., in the ability to filter effectively lengths of wave not only from the bottom through a color filter but also, and uniquely, in the upper part of the spectrum by means of physical water. Ellipse MFD technology is now even stronger, since the American patent has been granted to us to use water as one of our filters. Dual filtration mode combined with the technology of pulse square are the main reason why Ellipse uses much less energy compared to other IPL teams. The MFD allows us to filter and remove all the unnecessary wavelengths delimiting the light emitted to the chromophore to try avoiding nonspecific heating of the skin. in other words, Ellipse delivers only light spectrum that is absorbed in hemoglobin or melanin. This is the reason why the Ellipse systems do not need to refrigerate the skin during the treatment, since no heated water from the skin. For this reason, Ellipse systems require less energy than other IPL systems and in addition, achieve better results. It also allows us to deliver short or very long pulses without fragmenting them in pulse train. Pulse square technology ensures that energy reaches the desired level immediately, remains at that level while the...

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips